Compare Sanofi SA (SNY) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Total World Stock Index Fund ETF — how do they compare? Sanofi SA trades at $43.25 (market cap $104.57B), while Vanguard Total World Stock Index Fund ETF trades at $161.62. The key difference: Sanofi SA pays a 5.56% dividend while Vanguard Total World Stock Index Fund ETF pays none, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | VT | |
|---|---|---|
Market Cap | $104.57B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $52.34 | $161.30 |
52-Week Low | $41.33 | $132.19 |
Enterprise Value | $124.48B | — |
Dividend Yield | 5.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vanguard Total World Stock ETF (VT) trades at $161.3, up 0.86% on the day, with a bullish technical signal driven by moving averages. The ETF offers broad global diversification across over 10,000 stocks with a low 0.06% expense ratio. Recent institutional activity shows mixed positioning adjustments, while news highlights its role in global portfolios amid trade policy uncertainty.
VT presents a long-term diversification opportunity with low-cost global equity exposure, though near-term risks include trade war volatility and seasonal choppiness. The neutral oscillator signals and high short-term RSI suggest potential consolidation, but strong institutional interest supports its core holding appeal for risk-conscious investors seeking worldwide market access.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
